Revolutionize bispecific antibody development with common light chain technology
KYINNO SPONSORED CONTENT

Revolutionize bispecific antibody development with common light chain technology

Revolutionize bispecific antibody development with common light chain technology

Bispecific antibodies are a focal point in antibody drug development. However, conventional monoclonal antibodies may encounter challenges with light and heavy chain mismatch when used in bispecific antibodies. KYinno has developed CLC mice, featuring a fixed light chain sequence. This innovative approach circumvents light and heavy chain mismatch issues right from the beginning. Additionally, the CLC mouse’s light chain boasts high solubility and stability. Its CDR region exhibits low immunogenicity and is easily humanized. This combination of features positions CLC mice as an ideal animal model for the development of bispecific antibodies. Download this white paper to learn more.

Download Now

    Please fill out the information below to download the content. If you are already registered, or have requested a quote before, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

    • By submitting this form, you consent to Biocompare storing your email address and contact information and transmitting your contact information to the Future Lab sponsor. You also agree to receive email from Biocompare and the sponsor. You may request to be removed at any time.